GLP-1 Drugs Cut Bariatric Surgeries 34% as US Healthcare Shifts Toward Prevention
Updated
Updated · USA TODAY · Aug 20
GLP-1 Drugs Cut Bariatric Surgeries 34% as US Healthcare Shifts Toward Prevention
3 articles · Updated · USA TODAY · Aug 20
Summary
A JAMA study found bariatric surgeries fell 34% from 2022 to 2024 as GLP-1 use jumped 140%, reinforcing Wells Fargo’s view that obesity care is moving from operating rooms to drug treatment.
Semaglutide also reduced major cardiovascular events by 20% in overweight or obese adults without diabetes, pointing to fewer heart procedures and repeat hospital visits tied to obesity.
Doctors say the shift will not eliminate surgery entirely, with some patients stopping GLP-1s because of side effects, cost or limited results and later returning for operations.
$105 billion in projected global sales by 2030 underscores the stakes, but coverage remains a bottleneck as some employers and insurers drop benefits despite Medicare’s broader access for older adults.
That access question may determine whether lower overall healthcare spending materializes, even as newer drugs such as Eli Lilly’s Retatrutide show 19% to 28% weight loss in trials.
With hospitals losing lucrative surgeries to GLP-1s, who really pays the price when the medical system loses its biggest cash cows?
If patients must take weight-loss drugs forever, is the pharmaceutical industry actually curing the obesity epidemic or simply renting out the cure?
As these medications replace major surgeries, what hidden dangers are quietly brewing in the booming shadow market of unregulated compounded weight-loss drugs?